BALAXI PHARMACEUTICALS LIMITED (NSE:BALAXI) — Market Cap & Net Worth
Market Cap & Net Worth: BALAXI PHARMACEUTICALS LIMITED (BALAXI)
BALAXI PHARMACEUTICALS LIMITED (NSE:BALAXI) has a market capitalization of $14.13 Million (Rs1.31 Billion) as of June 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #26169 globally and #1455 in its home market, demonstrating a -2.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BALAXI PHARMACEUTICALS LIMITED's stock price Rs23.67 by its total outstanding shares 55207500 (55.21 Million). Review BALAXI total liabilities to assess the company's total debt and financial obligations.
BALAXI PHARMACEUTICALS LIMITED Market Cap History: 2015 to 2026
BALAXI PHARMACEUTICALS LIMITED's market capitalization history from 2015 to 2026. Data shows growth from $3.06 Million to $14.13 Million (22.73% CAGR).
BALAXI PHARMACEUTICALS LIMITED Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BALAXI PHARMACEUTICALS LIMITED's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
BALAXI PHARMACEUTICALS LIMITED's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.06x
BALAXI PHARMACEUTICALS LIMITED's market cap is 0.06 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.29 Million | $475.11K | -$803.73K | 4.82x | N/A |
| 2017 | $1.77 Million | $-6.14 Million | -$7.90 Million | -0.29x | N/A |
| 2018 | $3.40 Million | $-500.00 | -$7.72 Million | -6796.80x | N/A |
| 2019 | $9.68 Million | $135.95 Million | $19.66 Million | 0.07x | 0.49x |
| 2020 | $77.49 Million | $456.32 Million | $61.04 Million | 0.17x | 1.27x |
| 2021 | $61.18 Million | $2.31 Billion | $381.37 Million | 0.03x | 0.16x |
| 2022 | $72.51 Million | $2.79 Billion | $476.58 Million | 0.03x | 0.15x |
| 2023 | $51.63 Million | $3.36 Billion | $459.62 Million | 0.02x | 0.11x |
| 2024 | $43.17 Million | $2.41 Billion | -$23.87 Million | 0.02x | N/A |
| 2025 | $16.04 Million | $2.89 Billion | $250.70 Million | 0.01x | 0.06x |
Competitor Companies of BALAXI by Market Capitalization
Companies near BALAXI PHARMACEUTICALS LIMITED in the global market cap rankings as of June 19, 2026.
Key companies related to BALAXI PHARMACEUTICALS LIMITED by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
BALAXI PHARMACEUTICALS LIMITED Historical Marketcap From 2015 to 2026
Between 2015 and today, BALAXI PHARMACEUTICALS LIMITED's market cap moved from $3.06 Million to $ 14.13 Million, with a yearly change of 22.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs14.13 Million | -11.91% |
| 2025 | Rs16.04 Million | -62.84% |
| 2024 | Rs43.17 Million | -16.38% |
| 2023 | Rs51.63 Million | -28.80% |
| 2022 | Rs72.51 Million | +18.51% |
| 2021 | Rs61.18 Million | -21.05% |
| 2020 | Rs77.49 Million | +700.37% |
| 2019 | Rs9.68 Million | +184.91% |
| 2018 | Rs3.40 Million | +91.92% |
| 2017 | Rs1.77 Million | -22.66% |
| 2016 | Rs2.29 Million | -25.15% |
| 2015 | Rs3.06 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of BALAXI PHARMACEUTICALS LIMITED was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.13 Million USD |
| MoneyControl | $14.13 Million USD |
| MarketWatch | $14.13 Million USD |
| marketcap.company | $14.13 Million USD |
| Reuters | $14.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ve… Read more